NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions

Advanced TumorsMelanomaNon-Small-Cell Lung CancerErdheim-Chester DiseaseOther RAS/RAF/MEK/ERK Mutated Tumors

Interventions

DRUG

HH2710

HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.

Trial Locations (3)

47905

Horizon Oncology Research, LLC, Lafayette

48201

Barbara Ann Karmanos Cancer Institute, Detroit

Unknown

Shanghai East hospital, Shanghai